Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified October 2014 by Memorial Sloan-Kettering Cancer Center
Sponsor:
Collaborators:
MedImmune LLC
AstraZeneca
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT02227667
First received: July 17, 2014
Last updated: October 2, 2014
Last verified: October 2014
  Purpose

The purpose of this study is to find out what effects, good and/or bad, MEDI4736 has on the patient and cancer.

MEDI4736 is a type of medication called an antibody. Antibodies are normal proteins in the body that help fight infections and possibly cancer. MEDI4736 is a special type of an antibody produced in a laboratory. MEDI4736 works by blocking a specific protein called the Programmed Death Ligand-1 (PDL-1), located on tumor cells.


Condition Intervention Phase
Advanced Colorectal Cancer
Drug: MEDI4736
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study to Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Primary Outcome Measures:
  • best response rate [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    according to RECIST 1.1.


Secondary Outcome Measures:
  • Safety [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Subjects will be evaluated for occurrence of AEs at each visit. Events will be characterized and reported. Safety will also be monitored by performing physical exams and routine laboratory procedures. Terminology Criteria for Adverse Events" V4.0 (CTCAE).

  • Progression-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Progression-free survival will be measured from the start of treatment with MEDI4736 until the documentation of disease progression or death due to any cause, whichever occurs first.

  • Overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Overall survival will be determined as the time from the start of treatment with MEDI4736 until death


Estimated Enrollment: 48
Study Start Date: October 2014
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Patients with Advanced Colorectal Cancer
This will be a Simon two-stage design, single arm, phase II study. All subjects will receive MEDI4736 via IV infusion. Subjects will continue treatment for 12 months, or until progression of disease, initiation of alternative cancer therapy, unacceptable toxicity, or other reasons to discontinue treatment occur. Following the 12-month treatment period, subjects without evidence for progressive disease or other reason to discontinue treatment will be monitored without further treatment. Upon evidence of PD during the monitoring period, administration of MEDI4736 may resume for up to another 12 months.
Drug: MEDI4736
Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent obtained.
  • Histologically- or cytologically- confirmed CRC.
  • Pre-existing Tumor-Infiltrating Lymphocytes in an archived tumor specimen or fresh biopsy, defined as an average of ≥4 TILs/ High Power Field (HPF) in 5 consecutive HPFs, within the area with the highest TILs at low power; or, DNA mismatch repair deficiency, determined by immunohistochemistry or polymerase chain reaction per MSKCC institutional standard practice. DNA mismatch repair deficient tumors may be TIL positive or negative.
  • Locally advanced or metastatic CRC
  • Subjects have received two or more standard available therapies known to prolong survival and for which they would be considered eligible. At a minimum, such therapies should include regimens containing oxaliplatin and irinotecan in combination with a fluoropyrimidine (e.g., FOLFOX and FOLFIRI or their variants).
  • Age ≥ 18 years at time of study entry.
  • Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
  • Adequate organ and marrow function as defined below:
  • Absolute neutrophil count ≥ 1,500/mm3.
  • Platelet count ≥ 90,000/mm3.
  • AST and ALT ≤ 3 × institutional upper limit of normal (ULN) or ≤ 5 × ULN for subjects with liver metastases.
  • Bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN for subjects with documented/suspected Gilbert's disease.
  • Serum creatinine ≤ 1.5 x ULN;
  • Radiographically measurable disease per RECIST 1.1.
  • Life expectancy ≥ 16 weeks.
  • Willingness to provide consent for use of archived tissue for research purposes.
  • Subjects will be required to agree to a biopsy performed at baseline and again at week 8 of the study in order to be eligible for enrollment in stage 1 of the study
  • Females of childbearing potential who are sexually active with a nonsterilized male partner must use 2 methods of effective contraception from screening, and must agree to continue using such precautions for 90 days after the final dose of investigational product; cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control.
  • Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause).
  • Subjects must use 2 acceptable methods of effective contraception as described in below.
  • Nonsterilized males who are sexually active with a female partner of childbearing potential must use 2 acceptable methods of effective contraception from Day 1 and for 90 days after receipt of the final dose of investigational product.

Exclusion Criteria:

  • Anticancer therapy, monoclonal antibody or major surgery within 4 weeks prior to the first dose of MEDI4736.
  • Concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable.
  • Any prior Grade ≥ 3 irAE while receiving immunotherapy (including anti-CTLA-4 or anti-CD137 MAb) or any unresolved irAE of any grade (controlled irAE endocrinopathies are allowed).
  • Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.
  • Current or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
  • Any unresolved toxicity CTCAE >Grade 2 from previous anti-cancer therapy.
  • Active autoimmune disease within the past 2 years, except for mild conditions not requiring systemic treatment, such as vitiligo.
  • Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. NOTE: Local treatment of isolated lesions, excluding target lesions, for palliative intent is acceptable (e.g., by local ablation, surgery or radiotherapy).
  • Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, irritable bowel syndrome, ulcerative colitis).
  • Receipt of radiation therapy within 4 weeks prior to starting investigational product, or limited field of radiation for palliation within 2 weeks of the first dose of investigational product.
  • Known allergy or reaction to any component of the MEDI4736 formulation or its excipients.
  • Known central nervous system (CNS) metastases requiring treatment, such as surgery, radiation or steroids.
  • Known history of confirmed primary immunodeficiency.
  • History of organ transplant requiring therapeutic immunosuppression.
  • Other malignancy within 3 years, except for noninvasive malignancies such as cervical carcinoma in situ (CIS), non-melanomatous carcinoma of the skin or ductal carcinoma in situ (DCIS) of the breast that has/have been surgically cured, or prior malignancy considered by the investigator to be of low likelihood for recurrence.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any patient known to have active hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent.
  • Women who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.
  • Any other condition(s) that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
  • Subjects who are known to be HIV positive.
  • History of any chronic hepatitis as evidenced by:
  • Positive test for HBsAg and/or HBcAg.
  • Positive test for hepatitis C Antibody.
  • Receipt of live attenuated vaccination within 30 days prior to receiving MEDI4736
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02227667

Contacts
Contact: Neil Segal, MD PhD 646 888-4187
Contact: Leonard Saltz, MD 646-888-4286

Locations
United States, New York
Memorial Sloan Kettering Cancer Center Not yet recruiting
New York, New York, United States, 10065
Contact: Neil Segal, MD,PhD    646-888-4187      
Contact: Leonard Saltz, MD    646-888-4286      
Principal Investigator: Neil Segal, MD, PhD         
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
MedImmune LLC
AstraZeneca
Investigators
Principal Investigator: Neil Segal, MD, PhD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT02227667     History of Changes
Other Study ID Numbers: 14-109
Study First Received: July 17, 2014
Last Updated: October 2, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Memorial Sloan-Kettering Cancer Center:
MEDI4736
14-109

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases

ClinicalTrials.gov processed this record on November 25, 2014